Neonc Technologies Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Amir Farrokh Heshmatpour
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 23975 Park Sorrento Calabasas CA United States of America 91302
- IPO Date
- Mar 26, 2025
- CIK
- 0001979414
- Website
- neonctech.com
- Similar Companies
- Business
- NEONC Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company that develops proprietary, patented platform technologies to transport therapeutics across the blood-brain barrier for treating brain cancers and central nervous system (CNS) diseases; its lead candidates include NEO100, a purified perillyl alcohol formulation in Phase IIa clinical trials for recurrent glioblastoma with FDA Orphan Drug and Fast Track designations, NEO212, a conjugate of temozolomide and perillyl alcohol in Phase I/II trials for primary and secondary brain tumors via oral administration, and the broader NEO platform supporting intranasal and transfemoral delivery methods for enhanced therapeutic efficacy in CNS malignancies such as grade 4 astrocytoma. The company targets oncology biopharmaceutical markets, focusing on glioblastoma and other intracranial tumors, with operations centered in the United States and plans for expansion into the MENA region. Founded in 2008 and headquartered in Calabasas, California, NEONC holds exclusive worldwide rights from USC to an intellectual property portfolio of 135 U.S. and international patents issued and pending, extending protections to 2038. Recent developments include the completion of an $18.5 million financing round in 2024 that valued the company post-money at approximately $220 million and advanced Phase II trials under FDA Fast Track status; a strategic acquisition of advanced AI and 3D bioprinting intellectual property; the appointment of Ishwar Puri to its Board of Directors; initiation of Cohort 3 enrollment in the Phase 1 trial of NEO212; board approval in June 2025 for a $50 million equity investment and MENA expansion via non-binding term sheet with Quazar Investment, including 1.4 million shares at $25 per share and a sub-license agreement with NuroCure; and receipt of the Breakthrough Medical Technology Achievement Award from the California Investment Forum.
Company News
Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances
NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt
NeOnc's Powerful Brain Cancer Pipeline Advances
Powerful NeOnc Brain Cancer Pipeline Advances
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst
NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier
NeOnc Charting New Nasal Route to Treating Brain Cancer
NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results